THRB and cardiac hypertrophy: Indeed, reduced triglyceride levels and no liver injury, as assayed by serum levels of ALT, AST, and bilirubin, combined to the absence of cardiac hypertrophy, were observed in F344 rats exposed to a sub-chronic treatment with the two novel TRβ-agonists (74).